LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Song, J; Bergen, SE; Di Florio, A; Karlsson, R; Charney, A; Ruderfer, DM; Stahl, EA; Members of the International Cohort Collection for Bipolar Disorder (ICCBD); Chambert, KD; Moran, JL; Gordon-Smith, K; Forty, L; Green, EK; Jones, I; Jones, L; Scolnick, EM; Sklar, P; Smoller, JW; Lichtenstein, P; Hultman, C; Craddock, N; Landén, M; Smoller, JW; Perlis, RH; Lee, PH; Castro, VM; Hoffnagle, AG; Sklar, P; Stahl, EA; Purcell, SM ... view all 52 authors View less authors (2016)
Publisher: England
Journal: Molecular Psychiatry
Languages: English
Types: Article
Subjects: RC0321, Risk Factors, United Kingdom, Self Report, Genetic Variation, Lithium Compounds, Middle Aged, Antimanic Agents, Genotype, Biomarkers, Pharmacological, Carrier Proteins, Original Article, Lithium, Bipolar Disorder, Sweden, Genome-Wide Association Study, Polymorphism, Single Nucleotide, Genetic Predisposition to Disease, Adult, Female, Humans, Male
Lithium is the mainstay prophylactic treatment for bipolar disorder (BD), but treatment response varies considerably across individuals. Patients who respond well to lithium treatment might represent a relatively homogeneous subtype of this genetically and phenotypically diverse disorder. Here, we performed genome-wide association studies (GWAS) to identify (i) specific genetic variations influencing lithium response and (ii) genetic variants associated with risk for lithium-responsive BD. Patients with BD and controls were recruited from Sweden and the United Kingdom. GWAS were performed on 2698 patients with subjectively defined (self-reported) lithium response and 1176 patients with objectively defined (clinically documented) lithium response. We next conducted GWAS comparing lithium responders with healthy controls (1639 subjective responders and 8899 controls; 323 objective responders and 6684 controls). Meta-analyses of Swedish and UK results revealed no significant associations with lithium response within the bipolar subjects. However, when comparing lithium-responsive patients with controls, two imputed markers attained genome-wide significant associations, among which one was validated in confirmatory genotyping (rs116323614, P=2.74 × 10(-8)). It is an intronic single-nucleotide polymorphism (SNP) on chromosome 2q31.2 in the gene SEC14 and spectrin domains 1 (SESTD1), which encodes a protein involved in regulation of phospholipids. Phospholipids have been strongly implicated as lithium treatment targets. Furthermore, we estimated the proportion of variance for lithium-responsive BD explained by common variants ('SNP heritability') as 0.25 and 0.29 using two definitions of lithium response. Our results revealed a genetic variant in SESTD1 associated with risk for lithium-responsive BD, suggesting that the understanding of BD etiology could be furthered by focusing on this subtype of BD.

Share - Bookmark

Funded by projects

Cite this article